Drug profile

The FDA adverse-event record for Seresto Collar

39 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Seresto Collar. Species, reactions, and outcomes follow.

#1279 of 2,679
by report volume (all drugs)
39
adverse-event reports
5.1%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Seresto Collar ranks #1263 of 2679 by total reports (39). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1263
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Seresto Collar has 39 reports now versus 38 in that prior snapshot: 1 more (2.6%).

Report change
+1
Death-coded reports
+0
Death-coded share
−0.1 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Seresto Collar changes

Signature read: Seresto Collar's 5.1% death-coded share is among the lowest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
39
Total Reports
2
Deaths Reported
5.1%
Death-coded share of reports

Active Ingredients

Seresto Collar

Administration Routes

TopicalUnknown

Species Affected

Dog 34
Cat 5

Most Affected Breeds

Shepherd Dog - German 6
Retriever - Labrador 6
Domestic Shorthair 4
Retriever - Golden 4
Shepherd Dog - Australian 3
Spitz - German Pomeranian 2
Boxer (German Boxer) 2
Terrier - Bull - American Pit 2
Pit Bull 1
Terrier - Yorkshire 1

Most Reported Reactions

Lack of efficacy (ectoparasite) - tick NOS 7
Lack of efficacy (bacteria) - Borrelia 6
Seizure NOS 5
Lack of efficacy (ectoparasite) - flea 4
Lack of efficacy (bacteria) - Anaplasma 4
Vomiting 3
Lack of efficacy (bacteria) - Ehrlichia 3
Restlessness 2
Licking 2
Itching 2
Lack of efficacy (bacteria) - NOS 2
Fever 2

Outcome Breakdown

Ongoing
28 (71.8%)
Outcome Unknown
6 (15.4%)
Recovered/Normal
3 (7.7%)
Euthanized
2 (5.1%)

Seresto Collar: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Seresto Collar (#1279 of 2,679 by report volume); death-coded 5.1%. PlainBreed drug row · death-coded share stamp 5.1% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →